source
- Frontier Medicines CEO vows to accelerate cancer drug pipeline after recent layoffsFrontier Medicines announced that after a restructuring that included layoffs last year, the company is refocusing on its AI-driven proteomics platform to push more cancer therapies into clinical t…
- Bristol Myers Squibb ends partnership with Cellares, prompting the cell therapy maker to restructureBristol Myers Squibb announced that it is terminating its collaboration with Cellares after completing a comprehensive evaluation of the partnership. The decision was driven by BMS’s assessment th…